Is osteoporosis a peculiar association with primary biliary cirrhosis?

Table 1 Clinical details of the patients

	PBC	HCV+	Control group
Number of patients	35	49	33
Age (mean±SD), yr	52.5 ± 10	52.9 ± 5.8	51.8 ± 2.22
Age at menopause (mean±SD), yr	48.3 ± 4.5	48.5 ± 4.9	47 ± 7.46
BMI (mean±SD)	22.8 ± 3.2a	23.4 ± 4.2a	25.9 ± 4.29

^aP < 0.05 vs control group.

Table 2 Bone metabolism in PBC, in HCV+ patients and in healthy controls

	PBC	HCV+	Controls
BMD (lumbar spine)	0.810 ± 0.130	0.860 ± 0.140	0.972 ± 0.128
t-score≤–2.5 SD	–1.55 ± 0.99a	–0.39 ± 2.65	–0.29 ± 0.98
z-score	–0.94 ± 1.10c	–0.52 ± 1.23	–0.82 ± 1.02
25-OHD (nmol/L)	103.48 ± 58.85e	98.38 ± 44.65g	49.66 ± 19.72
BGP (mg/L)	8.80 ± 8.7	6.43 ± 11.14	9.56 ± 2.92
Intact (1–84) PTH (ng/L)	39.8 ± 26.3	35 ± 29.78	33.60 ± 11.77
Ca corr albumin (mg/dL)	2.27 ± 0.26	2.32 ± 0.13	2.31 ± 0.14

^aP < 0.05 vs controls.

^cP < 0.05 vs HCV+.

^eP < 0.05 vs controls.

^gP < 0.05 vs controls.

Table 3 Univariate analysis

Variable	n	Osteoporosis		P
		n	%
Menopausal status
Yes	46	10	(21.7)
No	38	2	(5.2)	0.032
Disease
HCV	49	7	(14.3)
PBC	35	5	(14.3)	1
Normal 25-OH vit D
Yes	67	10	(14.9)
No	17	2	(11.8)	0.739
Normal BGP
Yes	18	4	(22.2)
No	66	8	(12.1)	0.278
Serum PTH
Normal	48	5	(10.4)
High	36	7	(19.4)	0.242
BMI >23
Yes	56	4	(7.1)
No	28	8	(25.8)	0.008

Table 4 Multivariate analysis

Variable	Adjusted OR	95.0%CI		P
		Low	Upper
Disease (HCV vs PBC)	0.429	0.086	2.149	0.304
BGP	1.785	0.323	9.866	0.507
25-OH vit D	0.674	0.098	4.609	0.687
PTH	2.050	0.494	8.501	0.323
Menopausal status	23.102	1.524	350.186	0.024
BMI < 23	5.703	1.228	26.488	0.026
Age (yr)	1.151	1.004	1.320	0.044